Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 1665 | 2.63 |
09:41 ET | 600 | 2.68 |
09:43 ET | 5326 | 2.71 |
09:45 ET | 750 | 2.7071 |
09:48 ET | 100 | 2.74 |
09:50 ET | 655 | 2.73 |
09:52 ET | 100 | 2.72 |
09:57 ET | 100 | 2.73 |
09:59 ET | 500 | 2.7 |
10:01 ET | 100 | 2.71 |
10:03 ET | 100 | 2.73 |
10:10 ET | 2400 | 2.71 |
10:12 ET | 100 | 2.71 |
10:14 ET | 450 | 2.695 |
10:21 ET | 100 | 2.7 |
10:26 ET | 100 | 2.71 |
10:32 ET | 100 | 2.71 |
10:33 ET | 162 | 2.692 |
10:35 ET | 100 | 2.7 |
10:39 ET | 100 | 2.7 |
10:44 ET | 100 | 2.7 |
10:50 ET | 100 | 2.71 |
10:51 ET | 901 | 2.695 |
10:57 ET | 100 | 2.69 |
11:00 ET | 2420 | 2.67 |
11:04 ET | 1600 | 2.65 |
11:09 ET | 101 | 2.665 |
11:11 ET | 100 | 2.65 |
11:13 ET | 200 | 2.65 |
11:22 ET | 300 | 2.65 |
11:24 ET | 3200 | 2.66 |
11:26 ET | 517 | 2.6573 |
11:29 ET | 300 | 2.645 |
11:31 ET | 100 | 2.645 |
11:36 ET | 500 | 2.66 |
11:38 ET | 700 | 2.64 |
11:42 ET | 1400 | 2.64 |
11:45 ET | 750 | 2.64 |
11:47 ET | 200 | 2.64 |
11:49 ET | 100 | 2.64 |
11:51 ET | 100 | 2.65 |
11:56 ET | 4600 | 2.64 |
11:58 ET | 2200 | 2.65 |
12:02 ET | 200 | 2.665 |
12:03 ET | 400 | 2.665 |
12:05 ET | 100 | 2.68 |
12:07 ET | 1300 | 2.67 |
12:14 ET | 1200 | 2.6605 |
12:18 ET | 100 | 2.68 |
12:20 ET | 600 | 2.67 |
12:21 ET | 1533 | 2.67 |
12:23 ET | 200 | 2.68 |
12:25 ET | 4300 | 2.67 |
12:30 ET | 200 | 2.64 |
12:34 ET | 377 | 2.645 |
12:36 ET | 540 | 2.645 |
12:39 ET | 100 | 2.64 |
12:45 ET | 200 | 2.64 |
12:52 ET | 100 | 2.64 |
12:54 ET | 200 | 2.64 |
01:01 ET | 800 | 2.635 |
01:03 ET | 600 | 2.6385 |
01:12 ET | 2700 | 2.6161 |
01:17 ET | 400 | 2.61 |
01:26 ET | 2053 | 2.61 |
01:30 ET | 200 | 2.61 |
01:32 ET | 200 | 2.61 |
01:33 ET | 200 | 2.605 |
01:39 ET | 3194 | 2.61 |
01:53 ET | 300 | 2.61 |
01:57 ET | 200 | 2.615 |
02:02 ET | 100 | 2.62 |
02:06 ET | 2500 | 2.615 |
02:08 ET | 814 | 2.61 |
02:09 ET | 100 | 2.61 |
02:11 ET | 100 | 2.61 |
02:13 ET | 277 | 2.61 |
02:15 ET | 1000 | 2.61 |
02:20 ET | 800 | 2.61 |
02:22 ET | 802 | 2.6 |
02:24 ET | 2622 | 2.58 |
02:26 ET | 677 | 2.58 |
02:29 ET | 200 | 2.57 |
02:31 ET | 600 | 2.57 |
02:33 ET | 3026 | 2.59 |
02:36 ET | 1303 | 2.59 |
02:44 ET | 5342 | 2.61 |
02:45 ET | 200 | 2.61 |
02:58 ET | 500 | 2.6 |
03:00 ET | 100 | 2.6 |
03:02 ET | 1080 | 2.6 |
03:03 ET | 3100 | 2.5937 |
03:09 ET | 2400 | 2.6 |
03:12 ET | 200 | 2.595 |
03:14 ET | 1100 | 2.58 |
03:18 ET | 700 | 2.59 |
03:23 ET | 800 | 2.58 |
03:30 ET | 100 | 2.585 |
03:32 ET | 500 | 2.59 |
03:34 ET | 1865 | 2.59 |
03:36 ET | 100 | 2.595 |
03:39 ET | 200 | 2.595 |
03:43 ET | 100 | 2.595 |
03:45 ET | 100 | 2.595 |
03:50 ET | 3851 | 2.62 |
03:52 ET | 600 | 2.62 |
03:54 ET | 300 | 2.63 |
03:56 ET | 300 | 2.61 |
03:57 ET | 800 | 2.62 |
03:59 ET | 27735 | 2.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 142.6M | -0.7x | --- |
Vigil Neuroscience Inc | 145.5M | -1.6x | --- |
aTyr Pharma Inc | 144.0M | -1.9x | --- |
Invivyd Inc | 137.2M | -0.6x | --- |
Immunic Inc | 136.9M | -1.1x | --- |
Fractyl Health Inc | 133.7M | -1.8x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $137.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-3.77 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.